ButaPasteThis page contains information on ButaPaste for veterinary use.
The information provided typically includes the following:
- ButaPaste Indications
- Warnings and cautions for ButaPaste
- Direction and dosage information for ButaPaste
ButaPasteThis treatment applies to the following species:
FOR HORSES ONLY
Product Number 602-2010
NADA #116-087, Approved by FDA.
BUTAPASTE is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties.
Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones, and has the following structural formula:
Each 1 g marking on the plunger contains:
For the relief of inflammatory conditions associated with the musculoskeletal system in horses.
Use with caution in patients who have a history of drug allergy.
Not for use in horses intended for food.
Stop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of 2 weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate countermeasures.
In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.
Administration And Dosage:
Orally - 1 to 2 g of phenylbutazone per 500 lb of body weight, but not to exceed 4 g daily. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
Guidelines to Successful Therapy:
1. Use a relative high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
2. Response to BUTAPASTE therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
3. When administering BUTAPASTE the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.
4. Many chronic conditions will respond to BUTAPASTE therapy but discontinuance of treatment may result in recurrence of symptoms.
Store at 15°-30°C (59°-86°F).
Syringe containing 12 g of phenylbutazone.
KEEP OUT OF REACH OF CHILDREN
Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Net wt 60 g
Made in Ireland.
Manufactured for: BUTLER ANIMAL HEALTH SUPPLY, DUBLIN, OHIO 43017
NAC No.: 10822491
400 METRO PLACE NORTH, DUBLIN, OH, 43017-7545
|Every effort has been made to ensure the accuracy of the ButaPaste information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-09-05